Biotech

All Articles

Actinogen's cortisol blocker neglects phase 2 anxiety study

.Actinogen Medical's cortisol blocker has missed the major endpoint of a phase 2 research study in c...

Bivictrix chooses going private only means to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have actually been at the center of several a billion-dollar biobuc...

TPG leadings up funds to $580M for assets around life scientific researches

.Possession supervisor TPG, which has sustained biotechs such as Sionna Therapeutics as well as Sant...

Merck quits period 3 TIGIT test in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has experienced yet another misfortune. Months after shuttering a pha...

After a challenging year, Exscientia folds right into Recursion

.After a year described by pipeline cuts, the departure of its chief executive officer and unemploym...

Cullinan, after $25M package, restore bispecific to Harbour

.Cullinan Rehab was blown away sufficient along with Port BioMed's bispecific immune system reactor ...

A better examine Tough Biotech's Intense 15

.In this particular full week's incident of "The Top Line," our company are actually diving in to To...

Lilly experiences period 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's event commemorating the commendation...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and al...

Lykos are going to inquire FDA to reevaluate its own decision adhering to rejection of MDMA treatment for trauma

.Following a poor presenting for Lykos Rehabs' MDMA applicant for trauma at a current FDA advising b...